The collaboration includes a licence to use OXB’s LentiVector platform. Credit: Oxford Biomedica.

Oxford BioMedica (OXB) and Santen Pharmaceutical have agreed to jointly conduct research and development (R&D) activities for gene therapy products.

Under an R&D collaboration and an option and licence agreement, the companies will use OXB’s lentiviral vectors to generate pre-clinical, proof-of-concept evidence to discover treatments for inherited retinal disease.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The collaboration will also use OXB’s LentiVector platform and industrial-scale manufacturing capabilities.

Santen Pharmaceutical chief scientific officer and global R&D head Naveed Shams said: “We are excited to partner with Oxford Biomedica and leverage their lentiviral vector platform to develop innovative therapeutics for an inherited retinal disease.

“This important collaboration builds on Santen’s ongoing research efforts as part of the CiCLE Programme from the Japan Agency for Medical Research and Development, and further strengthens our commitment to addressing challenges in ophthalmic care.”

Under the partnership, OXB will receive an undisclosed milestone payment in addition to development milestones and royalties of up to 10% on net sales.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Santen will hold worldwide commercial rights to any drugs made as part of the programme, while OXB will be able to co-fund and participate in development and commercialisation activities in the US and Europe.

Inherited retinal diseases are rare disorders caused by more than 260 different genes. They are strong candidates for gene therapy as many of the responsible genetic mutations have already been identified.